TAKEDA PHARMACEUTICAL CO LTD
TAKEDA PHARMACEUTICAL CO LTD (TKPHF): 91 pipeline candidates · 184 clinical trials. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
N/A
N/A
Lead: Phase 3
91 candidates
N/A
N/A
A transparent, data-derived signal for TAKEDA PHARMACEUTICAL CO LTDacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$51.3B
Cash
—
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (91 candidates)
| Drug | Phase |
|---|---|
| [^11c]t-773 | Phase 1 |
| [14c] subasumstat | Phase 1 |
| 0.4% zoc2017217 | Phase 2 |
| adalimumab | Phase 4 |
| advate | Phase 3 |
| alectinib | Phase 4 |
| azilsartan | Phase 3 |
| bl-m07d1 | Phase 3 |
| bl-m24d1 | Phase 3 |
| bleomycin | Phase 3 |
Showing 10 of 91 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in TAKEDA PHARMACEUTICAL CO LTD's pipeline?
TAKEDA PHARMACEUTICAL CO LTD (TKPHF) has 91 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is TAKEDA PHARMACEUTICAL CO LTD's lead drug candidate?
TAKEDA PHARMACEUTICAL CO LTD's most advanced tracked candidate is [^11c]t-773 (Phase 1) for Healthy Volunteers.
What is TAKEDA PHARMACEUTICAL CO LTD's market capitalization?
TAKEDA PHARMACEUTICAL CO LTD's market capitalization is approximately $51.3B.
Who is the CEO of TAKEDA PHARMACEUTICAL CO LTD?
Mr. Christophe P. Weber is the chief executive officer of TAKEDA PHARMACEUTICAL CO LTD (TKPHF).
Get the full picture on TAKEDA PHARMACEUTICAL CO LTD
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.